FDA Limits Use Of Janssen COVID-19 Vaccine Due To Blood Clot, Death Risk
SILVER SPRING, Md. — The Food and Drug Administration on May 5 limited the authorized use of the Johnson & Johnson/Janssen Global Services LLC COVID-19 one-dose vaccine because of the risk...To view the full article, register now.
Already a subscriber? Click here to view full article